OBD will use their EpiSwitch™ Discovery Platform to resolve epigenetic knowledge around the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC). The data will be integrated with transcriptional profiling data to mechanistically and functionally characterize this process and develop a new class of potential NGC biomarkers.